Literature DB >> 33144411

IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.

Apostolos Karagiannis1, Eva Kassi2, Antonios Chatzigeorgiou1, Michael Koutsilieris3.   

Abstract

BACKGROUND/AIM: The insulin-like growth factor bioregulation system is implicated in cancer biology. Herein, we aim to review the evidence on the expression of the insulin-like growth factor 1 and 2 (IGF1 and IGF2), their receptors (IGF-Rs) and IGF-binding proteins (IGFBPs) in thyroid tissue and their possible association with benign and malignant thyroid nodular diseases.
MATERIALS AND METHODS: We systematically reviewed Pubmed and Scopus databases up to May 2020. A total of 375 articles were retrieved and analyzed.
RESULTS: Among 375 articles, 45 were included in this systematic review study. IGF1 was investigated in 31 studies, IGF2 in 1, IGF1 receptor in 15 and IGF-binding proteins in 13 articles. IGF1 expression in humans was dependent on the number and compound of benign nodules as well as the method of measurement. In differentiated thyroid carcinoma, a positive correlation between IGF1 and immunohistological stage was documented in some studies while in others only a positive trend was observed. IGF-1R and IGFBPs expression was higher in malignant rather than benign lesions. There was only a positive trend for increased IGF2 expression in malignancy, while IGFBPs were in most studies statistically increased in various cancer types compared to benign nodular disease.
CONCLUSION: The present data demonstrate that in most studies there is statistically positive expression of IGF-1 and less of IGF-2 in thyroid cancer compared to normal thyroid tissue. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Insulin-like growth factors; thyroid cancer; thyroid nodule

Mesh:

Substances:

Year:  2020        PMID: 33144411      PMCID: PMC7811675          DOI: 10.21873/invivo.12141

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  58 in total

1.  Insulin-like growth factor 1 expression in thyroid tumors.

Authors:  E Maiorano; A Ciampolillo; G Viale; P Maisonneuve; A Ambrosi; V Triggiani; E Marra; E Perlino
Journal:  Appl Immunohistochem Mol Morphol       Date:  2000-06

2.  Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study.

Authors:  Long Jin; Amber R Seys; Shuya Zhang; Michele R Erickson-Johnson; Christopher W Roth; Barbara R Evers; Andre M Oliveira; Ricardo V Lloyd
Journal:  Diagn Mol Pathol       Date:  2010-06

3.  IGF-IEc Expression Is Associated With Advanced Differentiated Thyroid Cancer.

Authors:  Apostolos K Karagiannis; Anastassios Philippou; Sofia Tseleni-Balafouta; Evaggelos Zevolis; Theodora Nakouti; Maria Tsopanomichalou-Gklotsou; Vasilis Psarras; Michael Koutsilieris
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

4.  Investigation of insulin resistance gene polymorphisms in patients with differentiated thyroid cancer.

Authors:  Mustafa Akker; Sibel Güldiken; Tammam Sipahi; Orkide Palabıyık; Ayhan Tosunoğlu; Özlem Çelik; Nermin Tunçbilek; Atakan Sezer; Necdet Süt
Journal:  Mol Biol Rep       Date:  2014-02-07       Impact factor: 2.316

Review 5.  The role of the IGF system in cancer growth and metastasis: overview and recent insights.

Authors:  Amir Abbas Samani; Shoshana Yakar; Derek LeRoith; Pnina Brodt
Journal:  Endocr Rev       Date:  2006-08-24       Impact factor: 19.871

6.  Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.

Authors:  Elias Sozopoulos; Helen Litsiou; Gerassimos Voutsinas; Nikolaos Mitsiades; Nikolaos Anagnostakis; Thomais Tseva; Efstratios Patsouris; Sofia Tseleni-Balafouta
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

7.  Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer.

Authors:  A Belfiore; G Pandini; V Vella; S Squatrito; R Vigneri
Journal:  Biochimie       Date:  1999-04       Impact factor: 4.079

8.  Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Authors:  Magdalena Slosar; Poonam Vohra; Manju Prasad; Andrew Fischer; Robert Quinlan; Ashraf Khan
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  INSULIN LIKE GROWTH FACTOR 1 POSSIBLE DEPENDENCE IN PATIENTS WITH METABOLIC SYNDROME OF NODULAR PATHOLOGY OF THE THYROID GLAND.

Authors:  M Rekvava; T Dundua; M Kobulia; L Javashvili; E Giorgadze
Journal:  Georgian Med News       Date:  2017-09

10.  Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition.

Authors:  Julie A Schmidt; Naomi E Allen; Martin Almquist; Silvia Franceschi; Sabina Rinaldi; Sarah J Tipper; Konstantinos K Tsilidis; Elisabete Weiderpass; Kim Overvad; Anne Tjønneland; Marie-Christine Boutron-Ruault; Laure Dossus; Sylvie Mesrine; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Pagona Lagiou; Dimitrios Trichopoulos; Antonia Trichopoulou; Domenico Palli; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Roberto Zanetti; H Bas Bueno-de-Mesquita; Petra H Peeters; Eiliv Lund; Virginia Menéndez; Antonio Agudo; María-José Sánchez; Maria-Dolores Chirlaque; Eva Ardanaz; Nerea Larrañaga; Joakim Hennings; Maria Sandström; Kay-Tee Khaw; Nick Wareham; Isabelle Romieu; Marc J Gunter; Elio Riboli; Timothy J Key; Ruth C Travis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-19       Impact factor: 4.254

View more
  1 in total

1.  Diosgenin From Dioscorea Nipponica Rhizoma Against Graves' Disease-On Network Pharmacology and Experimental Evaluation.

Authors:  Jingxin Xin; Wencong Cheng; Yongbing Yu; Juan Chen; Xinhuan Zhang; Shanshan Shao
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.